Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abbott, Jerini deal

ABT's Kos Life Sciences Inc. subsidiary returned North American rights to Jerini's icatibant (see

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE